Study splits incurable childhood brain tumors into 10 new diseases

September 28, 2017, Institute of Cancer Research
Credit: CC0 Public Domain

Scientists have found that deadly childhood brain tumours are actually 10 different diseases that should each be diagnosed and treated based on their specific genetic faults.

The major new study has important implications for treatment, since personalising care for each type of is likely to be much more effective than grouping them all together as one.

A team at The Institute of Cancer Research, London, found stark differences among 's 'high grade' , or gliomas, and that they could be split into at least 10 different cancers.

Some types should be far more treatable than others using drugs under development or already on the market.

The study, published today (Thursday) in Cancer Cell, is the world's largest of these aggressive childhood brain cancers and should lead to more accurate diagnostic tests to ensure each child receives the best possible treatment.

Many of the children had mutations in their tumours that can be targeted by existing drugs approved for adult cancers, demonstrating the benefit of testing children for in their tumours at the point of diagnosis.

The research was funded by The Institute of Cancer Research (ICR) itself along with many different charitable funders - Cancer Research UK, CRIS Cancer Foundation, Abbie's Army, The Lyla Nsouli Foundation, Christopher's Smile and the INSTINCT network funded by The Brain Tumour Charity, Great Ormond Street Hospital Children's Charity and Children with Cancer UK.

Researchers gathered genetic data from 910 cases from 20 previously published analyses and 157 new cases, from children or young adults up to the age of 30 with high-grade glioblastoma or diffuse intrinsic pontine glioma (DIPG).

Although rare, these are the biggest cause of cancer-related death in people under 19 years of age because survival rates are so poor - children with these tumours are only expected to live an average of 9-15 months.

It is therefore vital to find out more about their biology, what makes them so deadly, and how they might be treated.

The tumours could be split into different subtypes based on different characteristics, such as age at diagnosis, area of the brain, the number of genetic mutations and - crucially - errors in key genes that drive the disease.

One of the striking findings from the study was that while some children's tumours were driven by a single genetic error in which two genes were fused together, others had tens of thousands of genetic errors - among the highest number of mutations in any human cancer.

Tumours with mutations in a gene called BRAF were found to be much less aggressive than some of the other cancers, and actually shouldn't be classified as 'high grade' at all. These tumours could be susceptible to several adult cancer drugs that target BRAF mutations.

Scientists at the ICR, a research institute and charity, found mutations in common cancer genes such as PDGFRA, KIT, MYCN, EGFR, CDK6, and genes involved in DNA repair - all of which can be targeted by existing drugs.

They also uncovered numerous new potential therapeutic targets within each subtype, such as the gene TOP3A - a gene involved in DNA replication - in tumours with a specific type of histone mutation called H3.3K27M.

Three of the subtypes were distinguished by the presence or absence of different mutations in genes that produce histones - proteins that DNA is wrapped around to pack it tightly into cells. Histones are also involved in turning off and on certain genes - a role that can be very important in cancer.

Although there are currently no drugs that can target histone mutations, there are some in development and the presence or absence of these mutations gave clues about how aggressive the cancer is, and could point to future approaches to treatment.

The data produced by this study is now considered the definitive dataset on these cancers, and will be made available on a public data portal so the research community can use it to develop new tests and treatments.

Study leader Professor Chris Jones, Professor of Childhood Brain Tumour Biology at The Institute of Cancer Research, London, said:

"Our study uncovered a wealth of new information about children's brain cancers. We found that tumours that have historically been lumped together under one diagnosis are in fact comprised of many, remarkably different, diseases.

"Treating cancer based only on what we see down the microscope simply isn't good enough any more. We need to start thinking about these as completely different cancers and diagnosing and treating them based on their genetic faults. It's exciting that several types look like they could be clearly treatable using either existing drugs on the market or other treatments under development.

"We worked with colleagues across the world to gather enough data on these rare cancers to understand better what makes them so aggressive, and what occur that might make them susceptible to different treatments."

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

"A diagnosis with one of these high-grade brain tumours in children is devastating for families. We desperately needed to understand the biology of the diseases better if we are ever to find ways of treating them effectively. This important study is a vital step forward.

"We really need to get much better at making modern, targeted cancer treatments available for children, which means improving access to genetic testing and changing regulations so more drugs get tested in paediatric clinical trials."

Jo Williams lost her son Lucas after he was diagnosed with a brain tumour in May 2015. Jo and her husband Andrew set up the charity Lucas' Legacy in their son's name, to fund research into, and raise awareness of, childhood brain tumours. Jo said:

"We lost Lucas, our beautiful only child, in August 2015 following a short battle with a brain tumour. Before this Lucas had never been ill, or had a day off school. After a roller coaster of desperate hope and extreme despair, Lucas died at home - 11 weeks and one day after first becoming ill, and just four weeks away from his seventh birthday.

"After Lucas died, we were so sad to find out how little is invested in developing treatments for children with brain . The standard regimes that children receive for high-grade brain tumours are brutal, and Lucas went through so much. He fought so hard, but he deserved so much more, to have better treatments in his brave and courageous fight against this devastating illness.

"Professor Jones and his team are working hard to understand children's brain tumours better and to develop personalised treatments for children like Lucas, kinder treatments that will give them a better chance of survival.

"We are still so shocked that this happened to our seemingly healthy six-year-old boy. Lucas was a really kind, funny, clever, sporty boy and the centre of our world. We know that he would have grown up to be something really special. We know that he would have changed the world for the better. We still hope he will."

Explore further: Potential treatment for brain cancer as drug shrinks tumours

More information: Cancer Cell (2017). DOI: 10.1016/j.ccell.2017.08.017

Related Stories

Potential treatment for brain cancer as drug shrinks tumours

August 14, 2017
An international team of researchers has found a drug previously approved to treat breast cancer could also be used to shrink medulloblastoma, a common form of childhood brain tumour.

Immunotherapy treatment option for selected breast cancer patients, genetic study suggests

September 13, 2017
Immunotherapy drugs could help some breast cancer patients based on the genetic changes in their tumours, researchers at the Wellcome Trust Sanger Institute and their collaborators find. Published today (13 September) in ...

Children with cancer to get new gene test

March 31, 2016
Children with cancer at leading hospitals across the UK will be offered testing for genetic mutations in their tumours as part of a new initiative to begin to personalise children's cancer treatment.

Gene test could pinpoint patients sensitive to new type of cancer drug

December 22, 2016
Testing for a gene commonly mutated in ovarian cancers could pick out patients who will respond well to a promising new class of cancer drugs, a major new study reveals.

Genetic mutations found linked to rare cases of multiple bowel tumors

July 5, 2016
Researchers have identified genetic mutations affecting the immune system which may lead to the development of more than one bowel tumour at the same time. Understanding how these cancers develop could improve targeting of ...

Study links gene to aggressive form of brain cancer

June 12, 2015
Scientists have identified a gene mutation linked to the development of an aggressive form of brain cancer.

Recommended for you

Researchers stop spread of cancer in mice by blocking specific molecules

November 21, 2018
Melanoma skin cancer tumors grow larger and are more likely to metastasize due to interactions between a pair of molecules, according to experiments in mice and human cells. The results may restore the potential for a type ...

A study suggests that epigenetic treatments could trigger the development of aggressive tumours

November 20, 2018
A study headed by the Institute for Research in Biomedicine (IRB Barcelona) and published in the journal Nature Cell Biology examined whether the opening of chromatin (a complex formed by DNA bound to proteins) is the factor ...

'Druggable' cancer target found in pathway regulating organ size

November 20, 2018
It's known that cancer involves unchecked cell growth and that a biological pathway that regulates organ size, known at the Hippo pathway, is also involved in cancer. It's further known that a major player in this pathway, ...

Redefining colorectal cancer subtypes

November 20, 2018
There is a long-standing belief that colorectal cancer (CRC), which causes some 50,000 deaths in the United States each year, can be categorized into distinct molecular subtypes. In a paper published recently in the journal Genome ...

Proposed cancer treatment may boost lung cancer stem cells, study warns

November 20, 2018
Epigenetic therapies—targeting enzymes that alter what genes are turned on or off in a cell—are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant. Researchers at Boston ...

New drug discovery could halt spread of brain cancer

November 19, 2018
The tissues in our bodies largely are made of fluid. It moves around cells and is essential to normal body function.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.